Sutro Biopharma, Inc.
STRO
$0.8578
$0.01021.20%
NASDAQ
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Net Income | 76.05% | -30.50% | -333.20% | 1.01% | -24.64% |
Total Depreciation and Amortization | 6.15% | 7.89% | 7.91% | 3.45% | 3.41% |
Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
Total Other Non-Cash Items | 111.38% | 84.11% | 410.05% | -201.04% | 421.12% |
Change in Net Operating Assets | -204.57% | 44.96% | 27.09% | -290.27% | 514.23% |
Cash from Operations | -573.02% | -4.85% | -609.79% | -92.57% | 130.31% |
Capital Expenditure | 88.62% | -163.23% | 25.88% | -152.44% | 52.87% |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
Cash Acquisitions | -- | -- | -- | -- | -- |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | 103.35% | -123.37% | 501.21% | 230.28% | -217.50% |
Cash from Investing | 103.21% | -125.36% | 472.08% | 229.18% | -221.49% |
Total Debt Issued | -- | -- | -- | -- | -- |
Total Debt Repaid | -- | -- | 100.00% | 100.00% | 100.00% |
Issuance of Common Stock | -100.00% | -76.07% | -- | 14.36% | 9,110.59% |
Repurchase of Common Stock | -62.16% | 51.87% | -- | -124.24% | -516.67% |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | -- | -- | -- | -- | -- |
Cash from Financing | -100.06% | 101.92% | 99.23% | 117.72% | -29.91% |
Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | -265.05% | -1,968.27% | 225.15% | 154.67% | -85.19% |